A carregar...
Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
BACKGROUND. The use of immunotherapeutic agents, specifically immune checkpoint inhibitors (ICIs) for solid malignancies, is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) com...
Na minha lista:
| Publicado no: | Ann Surg Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7594106/ https://ncbi.nlm.nih.gov/pubmed/31965370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08183-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|